China healthcare pullback seen as a positioning window ahead of catalysts
AI summary card
China healthcare pullback seen as a positioning window ahead of catalysts
JPMorgan believes the April 23 decline in China healthcare was mainly driven by position-related profit-taking rather than deteriorating fundamentals, and that biotech, pharmaceuticals, and CXO will see dense clinical, outbound licensing, and order catalysts from 2Q26 through end-2026.
- On April 23, HSHCI fell 3.5%, while Akeso and 3SBio dropped about 13% and 10%, respectively, underperforming the Hang Seng Index, which fell about 1%; the report did not see any clear negative fundamental news.
- The report views the pullback more as profit-taking after crowded positioning ahead of ASCO, representing a constructive entry point to reposition into China healthcare, especially innovative drugs.
- Catalysts from 2Q26 to end-2026 include more China oral presentations at ASCO, key 1L NSCLC readouts, progress in ADC and bispecific platforms, FIC/BIC R&D, and more sustainable BD/out-licensing transactions.
- Preferred subsectors are biotech and CXO, with top recommendations being Innovent, Kelun Biotech, WuXi AppTec, and WuXi XDC.
Report interpretation
Overview
This report focuses on the investment opportunity in the China healthcare sector after the significant pullback on April 23, 2026. JPMorgan believes the decline was mainly driven by crowded positioning and profit-taking ahead of ASCO rather than negative fundamental news. The report emphasizes that China biotech and pharmaceuticals are entering a phase of structural change: commercialization of innovative drugs is accelerating, revenue quality is improving, ADCs and bispecific antibodies are becoming core differentiated platforms, BD/out-licensing is gradually becoming a repeatable earnings driver, and key indications such as 1L NSCLC will see major readouts concentrated in 2026.
Core views
The core view is that the pullback creates an opportunity to re-increase exposure to China healthcare, especially innovative drugs, biotech, and CXO. Three-year returns for biotech and pharma depend on scaled commercialization of innovative products, delivery of key clinical milestones, global competitiveness of differentiated platforms such as ADCs and bispecific antibodies, and whether BD monetization can continue to fund R&D and globalization. For CXO, the key lies in backlog growth, order conversion, GLP-1/TIDES and ADC-related outsourcing demand, as well as capacity and delivery execution. Retail pharmacies should be watched for traffic, same-store growth, network expansion, policy tailwinds, and M&A integration; medical devices should benefit from domestic recovery, overseas growth, product mix optimization, a new equipment cycle, and AI-enabled adoption.
Analysis framework
The report combines industry catalysts with a list of covered companies, first judging the nature of the April 23 decline, and then screening for names and subsectors most likely to drive share prices across dimensions such as ASCO, key clinical readouts, BD deals, innovative drug sales, CXO orders, and policy factors.
Methodology notes
Track ASCO, 1L NSCLC readouts, ADC/bispecific data, BD/out-licensing, and quarterly earnings from 2Q26 through end-2026.
This framework links short-term share price elasticity with medium-term fundamental changes to judge re-entry timing and priority allocation direction after the pullback.
Focus on evaluating first-in-class, best-in-class, ADC, bispecific antibodies, GLP-1, and non-oncology pipelines such as ophthalmology and immunology.
The report believes China innovative drugs no longer rely only on single oncology assets; platform depth, global partnerships, and non-oncology diversification will determine medium- to long-term value.
View out-licensing and global partnerships as a structural earnings source that reduces business model risk, supports R&D investment, and expands international influence.
Sustained BD income can improve revenue quality, ease R&D funding pressure, and validate global recognition of China innovative drug assets.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Innovent Biologics(1801.HK)Key recommended biotech name, rated OW, target price HK$111
- Strengths
- Potential 2027 product sales of Rmb20bn, a comprehensive pipeline spanning four major disease areas, a major BD deal with Takeda, and reasonable valuation.
- Weaknesses
- High reliance on Mazdutide sales, IBI363 clinical data, and scaling of the non-oncology business.
- Comparison
- The report lists it as one of the top biotech picks and emphasizes the importance of its non-oncology business and 1L NSCLC data to global competitiveness.
- Risks
- Mazdutide sales below expectations; disappointing IBI363 1L data; potential biosimilar VBP-driven pricing pressure.
- Kelun Biotech(6990.HK)Key recommended biotech name, rated OW, target price HK$535
- Strengths
- One of the purest ADC names in coverage; Sac-TMT partnered with Merck across 17 global Ph3 trials, with the potential to become a global best-in-class TROP2 ADC.
- Weaknesses
- Highly dependent on data from key ADC projects such as Sac-TMT and the pace of global approvals.
- Comparison
- The report directly links it to ADC globalization and its partnership with Merck, believing it has multiple clinical catalysts this year that could drive the share price.
- Risks
- Clinical failure in key Ph3 projects; domestic sales ramp slower than expected.
- Akeso(9926.HK)Leading bispecific antibody covered name, rated OW, target price HK$162
- Strengths
- Ivonescimab has the most important near-term NSCLC catalyst, with HARMONi-6 interim OS to be presented in the ASCO’26 plenary session.
- Weaknesses
- Valuation and market expectations are sensitive to HARMONi-6, HARMONi-3, and the U.S. BLA pathway.
- Comparison
- The report views it as a representative name in bispecific antibodies, with key focus on 1L sqNSCLC, 1L NSCLC, and the global registration pathway.
- Risks
- Failure in key Ph3 trials; domestic sales below expectations.
- Hengrui(600276.SS)Covered pharma name, rated OW, target price Rmb70
- Strengths
- Has 100+ innovative assets and 400+ clinical trials, BD deals provide recurring income, and the share of innovative drugs is rising rapidly.
- Weaknesses
- Still needs to offset declining generic drug revenue and prove that innovative drug growth and BD progress are fast enough.
- Comparison
- Compared with more focused innovative drug companies, Hengrui’s advantage lies in pipeline breadth and commercialization foundation.
- Risks
- Innovative drug sales below expectations; BD progress slower than expected; generic drug revenue declines faster than the ramp-up of innovative businesses.
- Hansoh Pharma(3692.HK)Top pharma pick, rated OW, target price HK$45
- Strengths
- Comprehensive pipeline, more attractive valuation than Hengrui, higher average BD quality, and FY26E drug sales and BD income are both expected to grow at double digits.
- Weaknesses
- Needs to prove the sustainability of growth in innovative product sales and BD income.
- Comparison
- The report lists it as the top pharma pick, emphasizing valuation and BD quality.
- Risks
- Innovative drug sales below expectations; BD progress slower than expected; failure in key clinical trials.
- WuXi AppTec(603259.SS/2359.HK)CXO/CDMO top pick, rated OW/OW, target price Rmb150/HK$150
- Strengths
- Global leader in small-molecule and peptide CDMO, FY26E sales growth guidance of 18-22%, strong order backlog, and reasonable valuation.
- Weaknesses
- Sensitive to order conversion, GLP-1 outsourcing demand, and the biotech financing environment.
- Comparison
- The report views it as one of the preferred CXO directions, with the key focus on TIDES and small-molecule development and manufacturing demand.
- Risks
- Geopolitical risk; financial performance below expectations.
- WuXi XDC(2268.HK)ADC CDMO top pick, rated OW, target price HK$77
- Strengths
- Global leader in integrated ADC CDMO, FY26E USD sales growth guidance of 30%, benefiting from ADC outsourcing and outbound China ADC deals.
- Weaknesses
- Highly dependent on ADC industry conditions, backlog conversion, and customer project advancement.
- Comparison
- The report directly links it to ADC leadership and global CRDMO service capabilities.
- Risks
- Geopolitical risk; financial performance below expectations.
Key data
- HSHCI performance on April 23-3.5%The Hang Seng Healthcare Index pulled back significantly, underperforming the Hang Seng Index, which fell about 1%.
- Akeso single-day performanceabout -13%The report includes it as an example of the significant pullback in healthcare on April 23.
- 3SBio single-day performanceabout -10%Likewise reflects concentrated selling pressure in the sector on April 23.
- Number of HSHCI single-day declines greater than 3% year to date6 timesThe report says these declines often occurred without clear negative fundamental news.
- Innovent potential product sales in 2027Rmb20bnThe table says Innovent could reach potential product sales of RMB 20 billion in 2027, with pipelines across four major disease areas and a major BD deal with Takeda.
- Hengrui innovative assets and clinical trials100+ innovative assets, 400+ clinical trialsThe report says Hengrui has one of the most comprehensive pipelines in China, with management guiding for 30% growth in FY26E innovative drug sales.
- WuXi AppTec FY26E sales growth guidance18-22%The table highlights it as a global leader in small-molecule and peptide CDMO with a strong order backlog.
- WuXi XDC FY26E USD sales growth guidance30%The table says it is a global leader in integrated ADC CDMO.
Impact & implications
If the report’s judgment is correct, the April 23 pullback could become a window to position for the next round of catalysts in China healthcare. For innovative drug names, the key variables will shift from sentiment repair to clinical data, BD delivery, and commercialization quality; CXOs will need to prove that GLP-1/TIDES, ADC-related project demand, and order conversion remain resilient. Conversely, if key Ph3 data fail, sales ramps disappoint, or pricing and volume-based procurement pressure exceed expectations, the pullback could evolve into a fundamental re-rating.
Risks
- Failure in key Ph3 clinical trials or data below market expectations, especially in 1L NSCLC, ADC, and bispecific antibody projects.
- Innovative drug sales ramping below expectations, leading to a reassessment of commercialization quality and revenue growth.
- Drug pricing, procurement reform, and potential VBP continuing to pressure traditional drug portfolios and margins for some innovative drugs.
- BD/out-licensing progress slower than expected, weakening recurring earnings drivers and global validation.
- CXO backlog conversion falling short of expectations, or GLP-1/TIDES and ADC-related outsourcing demand slowing.
- Geopolitical risk affecting the valuation and business visibility of CXO/CDMO names such as WuXi AppTec and WuXi XDC.
- If prescription outflow, store expansion, franchise management, or M&A integration at retail pharmacies fall below expectations, earnings recovery could be dragged down.
What to watch
- The quality of China innovative drug oral presentations and key abstracts at ASCO’26.
- IBI363 1L NSCLC PoC Ph1 data and progress of its head-to-head registrational data versus Keytruda.
- HARMONi-6 interim OS, HARMONi-3 interim PFS, HARMONi-2 final OS, and ivonescimab U.S. FDA approval milestones.
- Sac-TMT Ph3 PFS data in 1L PD-L1+ and PD-L1- NSCLC, and progress of the global Ph3 program with Merck.
- Innovative drug sales growth, BD deals, and quarterly earnings of companies such as Hengrui and Hansoh.
- 1Q26 and 1H26 results, FY26 guidance, backlog, and GLP-1/TIDES and ADC-related demand for WuXi AppTec and WuXi XDC.
- The actual impact of drug pricing and procurement policies on innovative drugs, CXO, and retail pharmacies.